Other substances

Burixafor

A CXC chemokine receptor 4 inhibitor.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Burixafor is a CXC chemokine receptor 4 inhibitor with hematopoietic stem cell-activator activity. Its efficacy has been assessed for the treatment of Multiple Myeloma, Hodgkin's Disease, and Non-hodgkin's Lymphoma (DrugBank).

Burixafor on PubChem

 

Structure image - Burixafor

C1CCC(CC1)NCCCNCC2CCC(CC2)CNC3=NC(=CC(=N3)N4CCN(CC4)CCP(=O)(O)O)N

Supporting references

Link Tested on Impact factor Notes Publication date
Prioritizing potential ACE2 inhibitors in the COVID-19 pandemic: Insights from a molecular mechanics-assisted structure-based virtual screening experiment
in silico 2.08

In silico screening of ACE2 inhibitors.

 Jul/23/2020
Export (.csv)